Advantage Alpha Capital Partners LP Has $496,000 Stock Position in Alkermes plc $ALKS

Advantage Alpha Capital Partners LP lessened its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 18.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,322 shares of the company’s stock after selling 4,035 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Alkermes were worth $496,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Diversified Trust Co increased its position in Alkermes by 0.8% during the 2nd quarter. Diversified Trust Co now owns 44,232 shares of the company’s stock valued at $1,265,000 after purchasing an additional 372 shares during the period. Quantbot Technologies LP boosted its stake in shares of Alkermes by 54.5% in the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after purchasing an additional 385 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Alkermes by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 77,000 shares of the company’s stock worth $2,203,000 after buying an additional 400 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Alkermes by 3.8% during the first quarter. PNC Financial Services Group Inc. now owns 12,352 shares of the company’s stock worth $408,000 after buying an additional 451 shares during the period. Finally, Amalgamated Bank raised its stake in Alkermes by 1.1% during the second quarter. Amalgamated Bank now owns 46,848 shares of the company’s stock worth $1,340,000 after buying an additional 528 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $30.38, for a total value of $273,420.00. Following the sale, the executive vice president owned 69,740 shares of the company’s stock, valued at $2,118,701.20. The trade was a 11.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 4.40% of the company’s stock.

Alkermes Stock Performance

Alkermes stock opened at $29.72 on Friday. The stock has a market cap of $4.91 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. Alkermes plc has a fifty-two week low of $25.17 and a fifty-two week high of $36.45. The firm’s 50-day simple moving average is $30.27 and its 200 day simple moving average is $29.45.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.08. The firm had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. As a group, analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ALKS shares. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the stock a “buy” rating in a report on Tuesday, October 28th. Needham & Company LLC boosted their target price on shares of Alkermes from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Truist Financial increased their target price on shares of Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, Mizuho increased their price objective on shares of Alkermes from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.69.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.